The AJMC® Psoriasis compendium is a comprehensive resource for clinical news and expert insights for the chronic skin disease, which tends to go through cycles where it flares and goes into remission.

Tildrakizumab Shows Clinical Improvement of Difficult-to-Treat Areas in Psoriasis

May 18th 2022, 7:35pm


Real-world patients with psoriasis demonstrated significant improvement in difficult-to-treat scalp, nail, palmoplantar, and genital disease manifestations with the IL-23 inhibitor tildrakizumab.

Greater Biologic Persistence, Adherence Achieved With Ixekizumab for Psoriasis

May 16th 2022, 7:45pm


Significantly greater persistence, adherence, and time on monotherapy was achieved with the use of ixekizumab vs the biologics adalimumab, etanercept, secukinumab, and ustekinumab, in the treatment of moderate to severe psoriasis.

Greater Psoriatic Arthritis Activity, Impact Observed in Low-Income Countries

May 14th 2022, 6:40pm


Patients with psoriatic disease who live in low-income countries exhibited the highest disease activity and impact despite similar usage of biologic drugs to that of higher-income areas.

Study Finds Bimekizumab Well Tolerated Long Term for Moderate to Severe Psoriasis

May 11th 2022, 3:00pm


Bimekizumab demonstrated a favorable long-term safety profile for the treatment of moderate to severe psoriasis, aside from an increased incidence of mild to moderate oral candidiasis that was also observed with short-term exposure.

Overlapping Comorbidity Risks Found in Patients With Plaque Psoriasis, Palmoplantar Pustulosis

May 5th 2022, 4:40pm


An overlapping comorbidity profile was observed among patients with plaque psoriasis and palmoplantar pustulosis, although risks of certain comorbid conditions varied between the 2 groups.

Cardiovascular Risk Significantly Greater in Patients With Psoriatic Disease

May 2nd 2022, 7:20pm


A significantly greater risk of cardiovascular events was observed among a multiethnic Brazilian population of patients with psoriasis and psoriatic arthritis vs controls, in which those in the sixth decade of life had the highest risk.

Dr Stephen Rozzo on Next Investigative Targets for Tildrakizumab in Psoriasis

April 30th 2022, 4:21pm


Stephen Rozzo, PhD, associate vice president and head, Biologics Medical Affairs, Sun Pharma, North America, discussed next steps in the evaluation of tildrakizumab for the treatment of psoriasis.

Lifestyle Behaviors Significantly Linked With Psoriasis Development Regardless of Genetic Risk

April 28th 2022, 1:58pm


Lifestyle behaviors, such as body mass index and smoking, were shown to have a greater predictive impact regarding development of psoriasis compared with genetic predisposition.

Dr Stephen Rozzo Discusses Real-world Efficacy of Tildrakizumab for Psoriasis

April 22nd 2022, 12:20pm


Stephen Rozzo, PhD, associate vice president and head, Biologics Medical Affairs, Sun Pharma, North America, discussed findings of 2 phase 4 real-world studies on tildrakizumab, which showed that patients achieved significant improvement in severity and quality of life by week 4 of treatment.

Ixekizumab Effective Long-term for Treatment of Psoriasis in Pediatric Patients

April 20th 2022, 5:20pm


Pediatric patients with psoriasis exhibited significant improvements in self-reported outcomes and objective measures of complete skin clearance when treated with ixekizumab vs placebo, with no new safety findings identified.